Annals of Oncology | VOL. 33
Read

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Publication Date Nov 1, 2022

Abstract

Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a moderate increase in pathological complete response (pCR) rate by an absolute 9% (P= 0.287). Patients with cT1b-cT4a-d triple-negative breast cancer (TNBC) received durvalumab 1.5 g or placebo every 4 weeks added to nab-paclitaxel 125 mg/m2 weekly for 12 weeks, followed by durvalumab/placebo every 4 weeks plus epirubicin/cyclophosphamide every 2 weeks followed by surgery. Durvalumab was not continued after surgery. The primary objective was pCR. Secondary endpoints included invasive disease-free survival (iDFS), distant disease-free survival (DDFS) and overall survival (OS). A total of 174 patients were randomised between June 2016 and October 2017. After a median follow-up of 43.7 months, 34 events had occurred. Despite a non-significant increase in the pCR rate, significant differences were observed for 3-year iDFS, DDFS and OS: iDFS was 85.6% with durvalumab versus 77.2% with placebo [hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.24-0.97, stratified log-rank P= 0.036]; DDFS 91.7% versus 78.4% (HR 0.31, 95% CI 0.13-0.74, P= 0.005); OS 95.2% versus 83.5% (HR 0.24, 95% CI 0.08-0.72, P= 0.006). pCR patients had 3-year iDFS of 95.5% with durvalumab and 86.1% without (HR 0.22, 95% CI 0.05-1.06). In the non-pCR cohort 3-year iDFS was 76.3% v...

Concepts

Distant Disease-free Survival pCR Rate Early Breast Cancer Addition Of Immune Checkpoint Inhibitors Neoadjuvant Chemotherapy In Triple-negative Breast Cancer Triple-negative Breast Cancer Hazard Ratio Confidence Interval Overall Survival Pathological Complete Response

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Climate change Research Articles published between Jan 16, 2023 to Jan 22, 2023

R DiscoveryJan 23, 2023
R DiscoveryArticles Included:  5

Carbon capture and utilization (CCU) is an emerging technology with commercial potential to convert atmospheric carbon dioxide (CO2) into net zero or ...

Read More

Quality Of Education Research Articles published between Jan 16, 2023 to Jan 22, 2023

R DiscoveryJan 23, 2023
R DiscoveryArticles Included:  2

Introduction: The Educational Scholar Program (ESP) is a creative method to focus on the quality of education and the scholarship of education. The ed...

Read More

Gender Equality Research Articles published between Jan 16, 2023 to Jan 22, 2023

R DiscoveryJan 23, 2023
R DiscoveryArticles Included:  5

This study deviates from the predominantly feminist/critical school of thought associated with existing gender studies to apply an interpretivist appr...

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.